Results 241 to 250 of about 212,526 (280)

Comprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Noncovalent Mechanistic Signatures. [PDF]

ACS Pharmacol Transl Sci
Darragh AC, Hanna AM, Lipner JH, King AJ, Servant NB, Jahic M.   +5 more
europepmc   +1 more source

Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]

Int J Mol Sci
Zhao Y, Chakraborty P, Tomassetti J, Subha T, Massé S, Thavendiranathan P, Billia F, Lai PFH, Abdel-Qadir H, Nanthakumar K.   +9 more
europepmc   +1 more source

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors. [PDF]

JCI Insight
Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun SH, Savardekar H, Li J, Jung KJ, Duggan MC, Lapurga G, Shaffer J, Scarberry L, Konda B, Verschraegen C, Kendra K, Shah M, Rupert R, Monk P, Shah HA, Noonan AM, Bixel K, Hays J, Wei L, Pan X, Behbehani G, Hu Y, Elemento O, Chung D, Xin G, Blaser BW, Carson WE.   +31 more
europepmc   +1 more source

E41K mutation activates Bruton's tyrosine kinase by stabilizing an inositol hexakisphosphate-dependent invisible dimer. [PDF]

J Biol Chem
Chowdhury S, Chakraborty MP, Roy S, Dey BP, Gangopadhyay K, Das R.   +5 more
europepmc   +1 more source

Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib. [PDF]

J Chem Inf Model
Barragan AM, Ghaby K, Pond MP, Roux B.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Journal of Medicinal Chemistry, 2022
Bruton's tyrosine kinase (BTK), a Tec family tyrosine kinase, is critical in immune pathways as an essential intracellular signaling element, participating in both adaptive and immune responses. Currently approved BTK inhibitors are irreversible covalent
T. D. Owens, K. Brameld, E. Verner, T. Ton, Xiaoyan Li, Jiang Zhu, M. Masjedizadeh, J. M. Bradshaw, R. Hill, D. Tam, A. Bisconte, Eun Ok Kim, M. Francesco, Y. Xing, J. Shu, D. Karr, Jacob LaStant, D. Finkle, Natalie Loewenstein, H. Haberstock-Debić, Michael J. Taylor, P. Nunn, C. Langrish, D. Goldstein   +23 more
semanticscholar   +1 more source

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of Medicinal Chemistry, 2019
Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas suggesting that inhibition of BTK is useful in the treatment of hematological malignancies.
Yunhang Guo, Ye Liu, N. Hu, D. Yu, Changyou Zhou, G. Shi, Bo Zhang, Min Wei, Jun-hua Liu, L. Luo, Zhiyu Tang, Huipeng Song, Yin Guo, X. Liu, D. Su, Shuo Zhang, Xiaomin Song, Xing Zhou, Yuan Hong, Shuaishuai Chen, Zhenzhen Cheng, S. Young, Q. Wei, Haisheng Wang, Qiuwen Wang, Lei Lv, Fan Wang, Haipeng Xu, Hanzi Sun, Haimei Xing, Na Li, Wei Zhang, Zhongbo Wang, Guodong Liu, Zhijian Sun, Dongping Zhou, Wei Li, Libin Liu, Lai Wang, Zhiwei Wang   +39 more
semanticscholar   +1 more source

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.

Biochemistry, 2018
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop ...
A. Buhimschi, Haley Armstrong, M. Toure, S. Jaime-Figueroa, Timothy L Chen, A. Lehman, J. Woyach, A. Johnson, J. Byrd, C. Crews   +9 more
semanticscholar   +1 more source

Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.

Journal of Medicinal Chemistry, 2020
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.
D. Angst, F. Gessier, P. Janser, A. Vulpetti, Rudolf Wälchli, C. Beerli, A. Littlewood-Evans, J. Dawson, B. Nuesslein‐Hildesheim, G. Wieczorek, S. Gutmann, C. Scheufler, A. Hinniger, A. Zimmerlin, Enrico G. Funhoff, R. Pulz, B. Cenni   +16 more
semanticscholar   +1 more source